靶向HER2胞外结构域Ⅳ的单克隆抗体在乳腺癌中的应用进展  

Clinical application and progression of monoclonal antibodies targeting HER2 extracellular domainⅣin breast cancer

作　　者：徐娇娇 陶佳妮 王晓稼[3] 陈占红[3] XU Jiaojiao;TAO Jiani;WANG Xiaojia;CHEN Zhanhong(the Second Clinical Medical College,Zhejiang Chinese Medical University,Hangzhou 310053,China;Postgraduate Training Base Alliance of Wenzhou Medical University(Zhejiang Cancer Hospital),Hangzhou 310022,China;Dept.of Breast Oncology,Zhejiang Cancer Hospital,Hangzhou 310022,China)

机构地区：[1]浙江中医药大学第二临床医学院,杭州310053 [2]温州医科大学研究生培养基地(浙江省肿瘤医院),杭州310022 [3]浙江省肿瘤医院乳腺内科,杭州310022

出　　处：《中国药房》2024年第5期635-640,共6页China Pharmacy

基　　金：中国抗癌协会-HER2靶点中国科研基金项目(No.CETSDSSCORP239-11)。

摘　　要：人表皮生长因子受体2(HER2)阳性乳腺癌侵袭性强且易转移,抗HER2靶向药物的应用能显著改善HER2阳性乳腺癌患者的预后。在已上市的HER2靶向药物中,靶向HER2胞外结构域Ⅳ的大分子单克隆抗体是治疗HER2阳性乳腺癌的基础靶向药物,主要包括曲妥珠单抗、伊尼妥单抗和马吉妥昔单抗。曲妥珠单抗用于乳腺癌全线治疗,循证医学证据充分,实践经验充足且安全性可控;伊尼妥单抗与曲妥珠单抗在HER2阳性转移性乳腺癌和新辅助/辅助治疗中疗效相似,且安全性可控;马吉妥昔单抗聚焦于携带CD16A-158F等位基因的患者,是晚期乳腺癌后线治疗的选择。临床上需根据患者具体病情选择最适合的药物。Human epidermal growth factor receptor 2(HER2)-positive breast cancer is aggressive and prone to metastasis,and the applications of HER2 agents have improved the prognosis of patients with HER2-positive breast cancer.Among the marketed HER2 agents,macromolecular monoclonal antibodies that target the extracellular domainⅣof HER2 were the cornerstone drugs of HER2-positive breast cancer,including trastuzumab,inetetamab,and margetuximab.Trastuzumab is available for the full-line treatment of breast cancer with sufficient proof of evidence-based medicine,sufficient practical experience and controllable safety.Inetetamab and trastuzumab have similar efficacy and controllable safety in HER2-positive metastatic breast cancer and neoadjuvant/adjuvant therapy.Margetuximab focuses on patients carrying the CD16A-158F allele,and is an option of posterior line treatment for advanced breast cancer.It is necessary to select the most suitable drugs clinically according to the specific condition of the patient.

关 键 词：乳腺癌 人表皮生长因子受体2阳性 细胞外结构域Ⅳ 单克隆抗体 曲妥珠单抗 伊尼妥单抗 马吉妥昔单抗 

分 类 号：R979.1[医药卫生—药品] R737.9[医药卫生—药学]